European Investment Bank invests in German MedTech – 20 million euros for PRECISIS
04.11.2025 17:00
PRECISIS GmbH, a Heidelberg-based MedTech company specializing in neuromodulation, has received €20 million in funding from the European Investment Bank (EIB). The venture capital loan will be used to accelerate clinical development, prepare for market expansion, scale up production, and expand market access in Europe.
„The innovative breakthroughs achieved through PRECISIS therapy are transforming the lives of epilepsy patients and their families – offering new hope and true freedom where previously there was only uncertainty. With €20 million in venture loans from the EIB, we are delighted to support PRECISIS and this pioneering work, which has been developed in Heidelberg and across Europe. This partnership demonstrates how targeted European innovation investments enable advances in medical research that can give millions of people in Europe and around the world a healthier, more fulfilling life,“ said Nicola Beer, Vice President of the European Investment Bank.
„This funding from the European Investment Bank is a strong endorsement of our platform and vision. It also marks a crucial milestone in our growth. With this initial funding round secured, we are now actively engaging with investors to close our Series B funding round and accelerate our entry into the US market. The opportunity for co-investors to participate at this stage – prior to global expansion – is extremely promising,“ said Karl Stoklosa, CEO of PRECISIS.
Dr. Angela Liedler, founder of PRECISIS, adds: „The partnership with the European Investment Bank is a milestone – not only for PRECISIS, but for the overarching vision we have pursued since day one: to bring meaningful innovations to the patients who need them most. I am proud and grateful to see how this financing now enables the next chapter of our growth and international impact.“
From idea to market-ready technology
PRECISIS's journey in the field of neurostimulation began in 2014 under the leadership of Dr. Angela Liedler in Heidelberg. Based on her clinical experience, she recognized that many people with focal epilepsy do not achieve sufficient seizure control despite medication. Together with an interdisciplinary team of neurologists, engineers, and physicists, she developed the concept of precise, reversible, and patient-friendly neurostimulation – targeted and without direct contact with the brain.
The result of this pioneering work is EASEE® – a novel, minimally invasive implant placed under the scalp that delivers targeted electrical impulses to epileptogenic brain regions. Unlike traditional deep brain stimulation or vagus nerve stimulation, EASEE® stimulates the affected areas from outside the skull – individually customizable for each patient and with significantly lower risk.
Proven effectiveness and market success in Europe
Current clinical data (Schulze-Bonhage A. et al., Epilepsia, 2025) demonstrate the high efficacy of the system: In 65 patients, the seizure frequency was reduced by at least half, the median seizure frequency decreased by 68 patients, and 81 patients continued the therapy even after two years.
EASEE® has been CE-certified since 2022 and is now actively used in six European countries – including Germany, Austria, Switzerland, the United Kingdom, Portugal, and Italy. Spain will follow shortly. With over 150 implanted patients, PRECISIS has crossed a significant market threshold and laid the foundation for its international rollout.
„The fact that we are now reaching clinical centers and patients across Europe is the result of years of research and close partnerships between medicine, technology and industry – supported by an interdisciplinary team that not only develops innovation but also successfully brings it into patient care,“ says Stoklosa.
European funding strengthens MedTech innovation
The EIB's venture loan was specifically designed for research-intensive companies with high social and economic potential – including to strengthen the European MedTech sector in a globally competitive environment. Earlier this year, the EIB Group launched the TechEU program to accelerate innovation and provide a total of €70 billion in financing between 2025 and 2027. By leveraging this support, TechEU aims to unlock up to €250 billion in investment in high-impact sectors such as life sciences, cleantech, and digital technologies in Europe.
The market for neurostimulation systems is considered one of the fastest-growing segments of the MedTech industry. Worldwide, approximately 15 million people are affected by focal epilepsy, with about a third of them not responding adequately to medication. For these patients, EASEE® offers a new therapeutic perspective – and for Europe, a leading role in a multi-billion-dollar market.
Milestones and future prospects
Since the creation of EASEE® in 2014, PRECISIS has achieved numerous significant milestones: CE certification in 2022, successful establishment in several European markets, the change of leadership to Karl Stoklosa in 2024, and the start of clinical expansion to the UK and Italy in 2025.
The company's innovative strength has also been recognized with several prestigious awards – including the Shark Tank Prize from the American Epilepsy Foundation, the Innovation BW Award in 2023, and the Health-i Award in 2024. Furthermore, PRECISIS was selected to participate in the MedTech Accelerator 2025, which further underscores the global potential and scalability of the innovation.
With the newly secured capital from Luxembourg, the company is now further advancing its growth strategy – with a clear focus on international approvals and access to the US market.
About PRECISIS GmbH
PRECISIS GmbH is an innovative medical technology company based in Heidelberg, specializing in neuromodulatory therapies for the treatment of neurological diseases.
Since its founding in 2004, PRECISIS has combined engineering excellence with medical expertise and a deep understanding of the needs of patients and physicians. With EASEE®, the first CE-certified, minimally invasive neurostimulation system for the treatment of drug-resistant focal epilepsy, PRECISIS is setting new standards in personalized neurotherapy.
Via the European Investment Bank
Over the past five years, the EIB Group has invested more than €22 billion in the life sciences and healthcare sectors. In 2024 alone, EIB-backed financing enabled an estimated 14.9 million people to access better healthcare services.
The European Investment Bank (EIB) is the European Union's long-term financing institution and is owned by its member states. It finances investments that contribute to achieving the EU's policy objectives – including climate action and the environment, digitalization and technological innovation, security and defence, cohesion, agriculture and bioeconomy, social infrastructure, capital markets union and a stronger Europe in a more peaceful and prosperous world.
The EIB Group, which includes the European Investment Fund (EIF), signed almost €89 billion in new financing for over 900 high-impact projects in 2024, thereby strengthening Europe's competitiveness and security.
All projects financed by the EIB Group are in line with the Paris Climate Agreement, as set out in the Climate Bank Roadmap. Around 60 million euros of the EIB Group's annual financing goes towards projects that directly contribute to combating climate change, adapting to its impacts, and creating a healthier environment.
To promote market integration and mobilize investment, the Group supported a record volume of over €100 billion for Europe's energy security in 2024 and mobilized €110 billion in growth capital for start-ups, scale-ups, and pioneering European companies. Around half of EIB financing within the EU flows into cohesion regions where per capita income is below the EU average.
The InvestEU program provides the European Union with long-term financing by mobilizing substantial private and public funds to foster a sustainable economy. It supports additional investment in line with EU policy priorities such as the European Green Deal, the digital transformation, and the promotion of small and medium-sized enterprises (SMEs). InvestEU brings together all EU financial instruments under one roof, making it easier, more efficient, and more flexible to finance investment projects in Europe. The program consists of three components: the InvestEU Fund, the InvestEU Advisory Centre, and the InvestEU Portal. The InvestEU Fund is implemented through financial partners who invest in projects using the EU Budget Guarantee of €26.2 billion. This guarantee increases their risk-bearing capacity, thereby mobilizing at least €372 billion in additional investment.